The rhizome of Pueraria lobata (family Leguminosae) is frequently used for the liver diseases, strokes, and allergy as a crude substance taken orally in Asian countries as a traditional ingredient of polyprescriptions.
Antithrombotic and Antiallergic Activities of Daidzein, a Metabolite of Puerarin and Daidzin Produced by Human Intestinal Microflora
To evaluate the antithrombotic activities of puerarin and daidzin from the rhizome of Pueraria lobata, in vitro and ex vivo inhibitory activities of these compounds and their metabolite, daidzein, were measured. These compounds inhibited ADP-and collagen-induced platelet aggregation. Daidzein was the most potent. However, when puerarin and daidzin were intraperitoneally administered, their antiaggregation activities were weaker than when these compounds were administered orally. When in vivo antithrombotic activities of these compounds against collagen and epinephrine were measured, these compounds showed significant protection from death due to pulmonary thrombosis in mice. To evaluate the antiallergic activity of puerarin, daidzin, and daidzein, their inhibitory effects on the release of b b-hexosaminidase from RBL 2H3 cells and on the passive cutaneous anaphylaxis (PCA) reaction in mice were examined. Daidzein exhibited potent inhibitory activity on the b bhexosaminidase release induced by DNP-BSA and potently inhibited the PCA reaction in rats. Daidzein administered intraperitoneally showed the strongest inhibitory activity and significantly inhibited the PCA reaction at doses of 25 and 50 mg/kg with inhibitory activity of 37 and 73%, respectively. The inhibitory activity of intraperitoneally administered daidzein was stronger than those of intraperitoneally and orally administered puerarin and daidzin. Therefore we believe that puerarin and daidzin in the rhizome of Pueraria lobata are prodrugs, which have antiallergic and antithrombotic activities, produced by intestinal microflora.
pended in Tyrode-HEPES buffer and used in the experiments.
Assay of in Vitro Antiplatelet Aggregation Platelet aggregation was measured by turbimetry using a dual-channel Whole Lumini-Ionized Calcium Aggregometer (Chrono-Log Co., Ltd., Havertown, PA, U.S.A.) according to the method of Born and Cross. 17) Briefly, rat PRP (300 ml) was incubated at 37°C for 2 min in the aggregometer with stirring at 1200 rpm and then stimulated with ADP and collagen. The samples or aspirin, as the reference agent, were incubated with PRP for 3 min, followed by the addition of the aggregation agents. Changes in light transmission were recorded for 10 min after stimulation with these agents. Each inhibition rate was obtained from the maximal aggregation induced by the respective agonist at several concentrations, and then the IC 50 values were calculated from the data using a Probit method.
In Vitro Coagulation Parameters The plasma clotting times, activated partial thromboplastin time (APTT), prothrombin time (PT), and thrombin time (TT) were measured according to the manufacturer's protocol. The PPP was incubated with the samples for 7 min at 37°C, and coagulation was started with by adding CaCl 2 , 100 ml of thromboplastin, and 100 ml of bovine thrombin to the 100 ml of incubated plasma for the APTT, PT, and TT assays, respectively.
Assay of ex Vivo Antiplatelet Aggregation Five male rats in each group were used after overnight fasting. Rats were orally or intraperitoneally administered the samples (25 or 50 mg/kg) as a vehicle. Blood was collected 3 h after sample treatment and PRP as previously described. Platelet aggregation was induced by 80 mg/ml of collagen or 8 mM of ADP. Antiplatelet activities of the sample were investigated according to the method of Kimura et al.
18)
Assay of in Vivo Antithrombotic Activity The antithrombotic effect in the samples was investigated using the mouse thromboembolism test according to the method of Di Minno et al. 19) Ten male ICR mice in each group were used after overnight fasting. The samples (25, 50 mg/kg) and 0.5% CMC solution were administered orally. A mixture solution of collagen (110 mg) and epinephrine (13 mg) was injected into the mouse tail vein 3 h after oral administration of the samples. The number of dead or paralyzed mice was recorded up to 15 min, and the percentage of protection was calculated as follows: [1Ϫ(deadϩparalyzed)/total]ϫ100.
Assay of Antiallergic Activity in RBL-2H3 Cell Line The inhibitory activity of tested compounds against the release of b-hexosamindase from RBL-2H3 cells was evaluated according to the method of Choi et al. 20) RBL-2H3 cells were grown in DMEM supplemented with 10% fetal bovine serum and L-glutamine. Before the experiments, cells were dispensed into 24-well plates at the concentration of 5ϫ10 5 cells per well using medium containing 0.5 mg/ml of mouse monoclonal IgE and were incubated overnight at 37°C in 5% CO 2 for sensitization of cells. The cells were washed with 500 ml of siraganian buffer (pH 7.2, 119 mM NaCl, 5 mM KCl, 0.4 mM MgCl 2 , 25 mM PIPES, 40 mM NaOH) and incubated in 160 ml of siraganian buffer containing 5.6 mM glucose, 1 mM CaCl 2 , and 0.1% BSA for an additional 10 min at 37°C. Then cells were exposed to 40 ml of test materials for 20 min, followed by treatment with 20 ml of antigen (DNP-BSA, 1 mg/ml) for 10 min at 37°C to activate cells to evoke allergic reactions (degranulation). The reaction was stopped by cooling in an ice bath for 10 min. The reaction mixture was centrifuged, and 25 ml aliquots of supernatant were transferred to 96-well plates and incubated with 25 ml of substrate (1 mM p-nitrophenyl-N-acetyl-b-D-glucosaminide) for 1 h at 37°C. The reaction was stopped by adding 0.1 N NaOH. The absorbance was measured using an ELISA reader at 405 nm.
Passive Cutaneous Anaphylaxis (PCA) reaction An IgE-dependent cutaneous reaction was measured according to the method of Katayama et al. 21) Five male ICR mice (25-30 g) in each group were used. Mice were injected intradermally with 10 mg of anti-DNP IgE into each of four dorsal skin sites that had been shaved 48 h earlier. The sites were outlined with a water-insoluble red marker. Forty-eight hours later, each mouse received an injection of 200 ml of 0.25% Evans blue-PBS containing 100 mg of DNP-HSA via the tail vein. Puerarin, daidzin, daidzein, or DSCG was administered 1 h prior to DNP-HSA injection. Thirty minutes after DNP-HSA injection, the mice were killed and their dorsal skins were removed for measurement of the pigmented area. After extraction with 1 ml of 1.0 N KOH and 9 ml of a mixture of acetone and phosphoric acid (5 : 13), the amount of dye was determined colorimetrically (absorbance at 620 nm).
Assay of Hyaluronidase Activity Hyaluronidase activity was determined using the method of Kakegawa et al.
13)
Assay of Antioxidant Activity DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging and XOD-inhibitory activities of compounds isolated were measured according to the method of Xiong et al. 22) Superoxide anion radical generation of compounds isolated was measured according to the method of Xiong et al. 22) RESULTS Antithrombotic Activities of Puerarin, Daidzin, and Daidzein In vitro inhibitory activities of puerarin, daidzin, and daidzein against ADP-and collagen-induced platelet aggregation were measured (Table 1) . These compounds inhibited ADP-and collagen-induced platelet aggregation. Daidzein was the most potent. Particularly, it inhibited platelet aggregation induced by collagen more potently than that induced by ADP. Its IC 50 were 0.2 and 0.05 mg/ml, respectively. Against ex vivo ADP-and collagen-induced rat platelet aggregation, these compounds also exhibited potent a) 50% inhibitory concentration (IC 50 ) was calculated as follows: (control aggregation (%)Ϫherbal medicine-treated aggregation (%))/control aggregation (%)ϫ100ϭin-hibition (%). b) Final concentration was 0.008 mM. c) Final concentration was 0.08 mg/ml. inhibitory activity (Table 2) . When puerarin and daidzin were administered intraperitoneally, their antiaggregation activities were weaker than when these compounds were administered orally. The rhizome of P. lobata did not inhibit in vitro ADPand collagen-induced platelet aggregation. However, it inhibited ex vivo ADP-and collagen-induced platelet aggregation even if orally administered at a high dose. Aspirin, a reference drug widely used as an antiplatelet aggregation agent in clinical practice, potently inhibited in vitro and ex vivo platelet aggregation. The antiplatelet aggregation activities of these compounds were more potent than that of aspirin.
In vitro inhibitory activities of these compounds against APTT, PT, and TT-induced human plasma coagulation were measured (Table 3) . These compounds did not show potent inhibitory activity. In vivo antithrombotic activities of these compounds against collagen and epinephrine were measured (Table 4) . These compounds and the rhizome of P. lobata gave significant protection against death due to pulmonary thrombosis in mice. Among them, intraperitoneally administered daidzein exhibited the most potent protective activity. Its activity was comparable to that of aspirin at the dose of 50 mg/kg.
Antiallergic Action of Puerarin, Daidzin, and Daidzein To evaluate the antiallergic activity of puerarin, daidzin, and daidzein, we then examined their inhibitory effects on the release of b-hexosaminidase from RBL-2H3 cells (Fig. 1) . All tested compounds exhibited inhibitory activity. Daidzein and daidzin inhibited more potently the release of b-hexosaminidase. Their inhibitory activities were comparable to that of DSCG. To determine their inhibitory effects on the PCA reaction in mice, these compounds were administered orally or intraperitoneally 60 min prior to challenge with antigen (Table 5 ). These compounds inhibited the PCA reaction on rats. Among the substances tested, daidzein administered intraperitoneally showed the strongest inhibitory activity and significantly inhibited the PCA reaction at doses of 25 and 50 mg/kg with inhibitory activity of 37 and 73%, respec- The samples were administered 3 h before tail vein injection of epinephrine and collagen, and the assay of antithrombotic activity was performed according to Materials and Methods. tively. The inhibitory activity of intraperitoneally administered daidzein was stronger than that of intraperitoneally and orally administered puerarin and daidzin.
To understand the antiallergic mechanism of these compounds, we measured their hyaluronidase activation inhibitory and antioxidant activities (Table 6 ). No tested compounds inhibited hyaluronidase activation. Puerarin and daidzin did not show antioxidant activity against DPPH and free radical-scavenging activities. However, daidzein showed potent antioxidant activity against DPPH and free radicalscavenging activities.
DISCUSSION
The rhizome of P. lobata, an ingredient of many polyprescriptions, has been used to treat liver diseases, stroke, and allergy. Its main components are puerarin and daidzin. These glycosides are not easily absorbed from intestine to blood due to their hydrophilic properties. Therefore these components are metabolized to daidzein by human intestinal microflora before absorption. 15) When puerarin and daidzin were administered orally to rats, daidzein in the urine was the main metabolite. 10, 11) We also identified daidzein in urine, when puerarin and daidzin were administered orally (data not shown). When puerarin and daidzin were incubated with the liver homogenate of mice, puerarin was not transformed to daidzein and daidzin was very weakly transformed to daidzein (Table 7) . However, human fecal suspension potently transformed puerarin and daidzin to daidzein. These results suggest that puerarin and daidzin could be transformed to daidzein before absorption into the blood. Therefore we investigated the antithrombotic and antiallergic activities of puerarin, daidzin, and their metabolite daidzein to evaluate the role of the intestinal bacteria on the pharmacological actions.
First, platelets play an important role in the pathogenesis of thrombosis. The interactions between platelets and blood vessel walls are important in the development of thrombosis and cardiovascular disease such as myocardial infarction, stroke, and arteriosclerosis. [23] [24] [25] Once blood vessels are damaged, platelet aggregation occurs rapidly to form hemostatic plugs or arterial thrombi at the sites of vessel injury or in regions where blood flow is disturbed. These thrombi are the source of thromboembolic complications of arteriosclerosis, heart attacks, stroke, and peripheral vascular disease. [26] [27] [28] Therefore the inhibition of platelet function represents a promising approach for the prevention of thrombosis. Puerarin, daidzin, and daidzein exhibited inhibitory activity against platelet aggregation in vitro and ex vivo and protected against thromboembolism in mice. Daidzein, which is a metabolite of puerarin and daidzin produced by human intestinal microflora before absorption in the intestine, was the most potent. The rhizome of P. lobata also exhibited in vitro and ex vivo antiplatelet aggregation activity even if it was administered orally at high dose. The rhizome of P. lobata potently protected against thromboembolism. Based on these findings, the rhizome of P. lobata, particularly daidzein, if puerarin and daidzein are metabolized to daidzein by human intestinal bacteria, could prevent the development of recurrence and thrombosis.
Second, DSCG is an antiallergic drug. 29) This drug inhibited the release of b-hexosaminidase from RBL-2H3 cells by DNP-BSA, which is an essential step in the pathological process of type I allergy. 20) These facts suggest that, if substances that strongly inhibit b-hexosaminidase release are discovered, they could be lead compounds for developing new antiallergic drugs. In the present study, we investigated the inhibitory activity of puerarin, daidzin, and daidzein on b-hexosaminidase release from RBL-2H3 cells. These compounds inhibited b-hexosaminidase release, with daidzein being the most potent. Daidzein showed potent antioxidant activity against free radical-scavenging activities. These results support the reports that antioxidants are useful for treating allergic diseases. 30) Daidzein also had the most potent inhibitory activity against the PCA reaction. These results suggest that, when puerarin and daidzin are administered orally, it is easily metabolized to daidzein in intestine, and daidzein is absorbed into blood and is responsible for the inhibitory activity against PCA reaction.
In this study, daidzein, the metabolite of puerarin and daidzin produced by human intestinal bacteria, demonstrated the potent inhibitory activity against thrombosis and allergy. Finally, we believe that puerarin and daidzin in the rhizome of P. lobata are prodrugs that have extensive antiallergic and antithrombotic properties. a) The reaction mixture containing 0.3 ml of 1 mM puerarin (or daidzin), 0.1 ml of an enzyme source, and 0.6 ml of 10 mM sodium phosphate buffer pH 7.0, was incubated at 37°C at 2 h, and extracted with 2 ml of ethylacetate, and analyzed by TLC (developing solvent, CHCl 3 : MeOHϭ4 : 1) scanner (Shimadzu CS-9301PC). b) Livers of ICR mice were homogenized in 20 mM sodium phosphate buffer, pH 7.0, and centrifuged at 5000ϫg for 30 min. The resulting supernatant was used as a crude enzyme. c) Fresh human feces were suspended in 20 mM sodium phosphate buffer, pH 7.0, and centrifuged at 100ϫg for 10 min. The supernatant was centrifuged at 5000ϫg for 30 min. The precipitate was sonicated by ultrasonic and centrifuged at 5000ϫg for 30 min. The resulting supernatant was used as a crude enzyme. The results were expressed as meanϮS.D. (nϭ5).
